MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Robin Guo; Lynne D. Berry; Dara L. Aisner; Jamie Sheren; Theresa A. Boyle; Paul A. Bunn; Bruce E. Johnson; David J. Kwiatkowski; Alexander Drilon; Lynette M. Sholl; Mark G. Kris

doi:10.1016/j.jtho.2019.06.009

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Authors: Robin Guo, Lynne D. Berry, Dara L. Aisner, Jamie Sheren, Theresa A. Boyle, Paul A. Bunn, Bruce E. Johnson, David J. Kwiatkowski, Alexander Drilon, Lynette M. Sholl, Mark G. Kris - Journal of Thoracic Oncology 2019 cited by 174

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium | Litlas